NASDAQ:IRTC - Irhythm Technologies Stock Price, Forecast & News

Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."

Irhythm Technologies Inc (NASDAQ:IRTC) announced its earnings results on Tuesday, November, 5th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.34. The business earned $55.96 million during the quarter, compared to the consensus estimate of $53.76 million. Irhythm Technologies had a negative net margin of 26.45% and a negative return on equity of 67.44%. The company's revenue was up 46.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.43) EPS. View Irhythm Technologies' Earnings History.

Irhythm Technologies is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Irhythm Technologies.

Irhythm Technologies will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Irhythm Technologies issued an update on its FY 2019 Pre-Market earnings guidance on Monday, December, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $213-214 million, compared to the consensus revenue estimate of $216.89 million.

7 equities research analysts have issued twelve-month price objectives for Irhythm Technologies' shares. Their forecasts range from $90.00 to $125.00. On average, they anticipate Irhythm Technologies' stock price to reach $106.80 in the next year. This suggests a possible upside of 22.7% from the stock's current price. View Analyst Price Targets for Irhythm Technologies.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Irhythm Technologies.

Media stories about IRTC stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Irhythm Technologies earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the company's share price in the immediate future. View News Stories for Irhythm Technologies.

Some companies that are related to Irhythm Technologies include Novocure (NVCR), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), NuVasive (NUVA), Cantel Medical (CMD), Glaukos (GKOS), Merit Medical Systems (MMSI) and Inspire Medical Systems (INSP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Irhythm Technologies investors own include Twilio (TWLO), Tandem Diabetes Care (TNDM), Alibaba Group (BABA), Canopy Growth (CGC), Paycom Software (PAYC), DexCom (DXCM), NVIDIA (NVDA), Paypal (PYPL), Splunk (SPLK) and BioTelemetry (BEAT).

(IRTC) raised $76 million in an initial public offering (IPO) on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Irhythm Technologies' stock is owned by a number of of retail and institutional investors. Top institutional investors include Capital Research Global Investors (7.91%), William Blair Investment Management LLC (4.64%), Alliancebernstein L.P. (3.38%), Franklin Resources Inc. (2.56%), State Street Corp (2.53%) and Victory Capital Management Inc. (1.86%). Company insiders that own Irhythm Technologies stock include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Merz Cathleen Noel Bairey, Raymond W Scott and Vijay K Lathi. View Institutional Ownership Trends for Irhythm Technologies.

IRTC stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Franklin Resources Inc., Lord Abbett & CO. LLC, Sectoral Asset Management Inc, Goldman Sachs Group Inc., Fiera Capital Corp, Man Group plc and First Trust Advisors LP. Company insiders that have sold Irhythm Technologies company stock in the last year include Bruce G Bodaken, David A Vort, Kevin M King, Matthew C Garrett and Merz Cathleen Noel Bairey. View Insider Buying and Selling for Irhythm Technologies.

IRTC stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Renaissance Technologies LLC, Capital Research Global Investors, Alliancebernstein L.P., Victory Capital Management Inc., State Street Corp, Victory Capital Management Inc. and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Irhythm Technologies.

Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRTC stock can currently be purchased for approximately $87.02.

Irhythm Technologies has a market capitalization of $2.32 billion and generates $147.29 million in revenue each year. The company earns $-48,280,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Irhythm Technologies employs 748 workers across the globe.View Additional Information About Irhythm Technologies.

The official website for Irhythm Technologies is http://www.irhythmtech.com/.

Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]